The presence of tumor‐resident CD103+ TILs could also represent a good candidate marker of response to immunotherapy as this TIL population seems to express PD‐1 (Djenidi et al., 2015; Komdeur et al., 2016). The gene discussed is ITGAE; the disease is neoplasm.